Lack of effect of gliclazide on early diabetic nephropathy and retinopathy: a two-year controlled study

George Jerums, Robin M.L. Murray, Ego Seeman, Mark E. Cooper, Sally Edgley, Keith Marwick, Richard G. Larkins, Thomas J. Martin

Research output: Contribution to journalArticleResearchpeer-review

22 Citations (Scopus)


This study has attempted to document a specific haemovascular action of gliclazide on the reversal of early diabetic microangiopathy. A prospective double-blind controlled study was performed over 2 years, comparing gliclazide versus placebo in insulin-treated and gliclazide versus glibenclamide in non-insulin-treated diabetic subjects, after a 1-year run-in period. Glycaemic control was not significantly different in gliclazide-and non-gliclazide-treated subjects before or after the commencement of active therapy. Following treatment with gliclazide in 17/32 insulin-treated and 8/17 non-insulin-treated subjects with Albustix-negative proteinuria, there was no difference in retinopathy score, total proteinuria or the renal clearance of creatinine, albumin, transferrin and immunoglobulin G. In the insulin-treated group, progression of retinopathy was observed in approximately one-third of subjects, but no parameter of proteinuria progressed over 2 years. Thus, this study did not detect a reversal of the parameters measured and does not support an action of gliclazide on diabetic microangiopathy, independent of its hypoglycaemic action.

Original languageEnglish
Pages (from-to)71-80
Number of pages10
JournalDiabetes Research and Clinical Practice
Issue number2
Publication statusPublished - 1 Jan 1987
Externally publishedYes


  • (Diabetic)
  • Gliclazide
  • Microangiopathy
  • Renal protein clearance
  • Retinopathy

Cite this